Pacific Capital Partners Ltd Acquires 8,250 Shares of Becton, Dickinson and Company $BDX

Pacific Capital Partners Ltd grew its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 28.2% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 37,500 shares of the medical instruments supplier’s stock after purchasing an additional 8,250 shares during the period. Becton, Dickinson and Company comprises 7.7% of Pacific Capital Partners Ltd’s investment portfolio, making the stock its largest holding. Pacific Capital Partners Ltd’s holdings in Becton, Dickinson and Company were worth $7,278,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. SOA Wealth Advisors LLC. boosted its position in Becton, Dickinson and Company by 256.8% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 95 shares during the period. Activest Wealth Management lifted its stake in shares of Becton, Dickinson and Company by 285.3% during the third quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 97 shares in the last quarter. Imprint Wealth LLC purchased a new stake in shares of Becton, Dickinson and Company in the third quarter worth about $25,000. Cornerstone Planning Group LLC boosted its position in shares of Becton, Dickinson and Company by 463.3% in the third quarter. Cornerstone Planning Group LLC now owns 169 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 139 shares during the period. Finally, Accredited Wealth Management LLC grew its stake in shares of Becton, Dickinson and Company by 77.8% in the third quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 70 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

BDX stock opened at $154.45 on Tuesday. The stock’s 50 day moving average is $179.58 and its two-hundred day moving average is $187.35. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $187.35. The company has a market capitalization of $43.98 billion, a PE ratio of 25.20, a P/E/G ratio of 11.20 and a beta of 0.24. The company has a quick ratio of 0.58, a current ratio of 1.05 and a debt-to-equity ratio of 0.67.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, beating the consensus estimate of $2.81 by $0.10. The company had revenue of $5.25 billion during the quarter, compared to analysts’ expectations of $5.15 billion. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The business’s revenue was up 1.6% on a year-over-year basis. During the same period in the prior year, the business posted $3.43 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be issued a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 68.52%.

Becton, Dickinson and Company announced that its board has initiated a stock buyback plan on Tuesday, January 27th that permits the company to buyback $10.00 million in outstanding shares. This buyback authorization permits the medical instruments supplier to purchase up to 0% of its shares through open market purchases. Shares buyback plans are often an indication that the company’s management believes its stock is undervalued.

Wall Street Analysts Forecast Growth

Several research firms recently commented on BDX. Wells Fargo & Company reduced their price target on Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 10th. Morgan Stanley lifted their price objective on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a research note on Tuesday, December 2nd. Jefferies Financial Group reduced their target price on shares of Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating on the stock in a research report on Tuesday, February 10th. Piper Sandler restated a “neutral” rating and issued a $170.00 target price (down from $205.00) on shares of Becton, Dickinson and Company in a research note on Tuesday, February 10th. Finally, Stifel Nicolaus lifted their price target on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Six analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Hold” and a consensus price target of $191.62.

Insider Activity

In related news, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the transaction, the executive vice president directly owned 12,095 shares in the company, valued at approximately $2,509,228.70. This trade represents a 11.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bertram L. Scott sold 953 shares of the business’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total value of $174,027.33. Following the completion of the sale, the director directly owned 36,763 shares of the company’s stock, valued at approximately $6,713,291.43. This represents a 2.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 2,713 shares of company stock valued at $536,881 in the last three months. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.